RTN4R and neoplasm: Even though anti-tumour activity was not a primary end point of this study, the high disease control rate (73%) achieved in a population heavily pre-treated with chemotherapy, including 9 patients (60%) with an anthracycline-based regimen, seem to be promising by also taking into account the minimal toxicity profile associated to NGR–hTNF and the apparent absence of overlapping toxicity with doxorubicin.